SP1 and COVID-19: Combining the results of HLA-A*02:01 binding capability, the proportion of antigen-specific CD8+ T cells in HLA-A2-positive convalescent COVID-19 patients, and the ability to activate T cells, we therefore propose that n-Sp1 is the dominant CD8+ T-cell epitope specific to SARS-CoV-2.